ICU Medical, Inc. (NASDAQ:ICUI – Get Free Report) crossed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $149.89 and traded as high as $164.15. ICU Medical shares last traded at $161.24, with a volume of 153,808 shares trading hands.
Wall Street Analysts Forecast Growth
Several equities research analysts recently commented on the stock. Zacks Research lowered shares of ICU Medical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Weiss Ratings raised shares of ICU Medical from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, October 8th. Needham & Company LLC lifted their target price on shares of ICU Medical from $165.00 to $187.00 and gave the company a “buy” rating in a report on Friday, August 7th. Raymond James Financial reiterated a “strong-buy” rating and set a $200.00 target price on shares of ICU Medical in a report on Friday, August 7th. Finally, Wall Street Zen raised ICU Medical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 8th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, ICU Medical has a consensus rating of “Moderate Buy” and an average price target of $192.80.
Read Our Latest Stock Report on ICU Medical
ICU Medical Stock Down 0.1%
The company has a market capitalization of $4.02 billion, a PE ratio of 136.31, a P/E/G ratio of 2.03 and a beta of 0.86. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.21 and a current ratio of 2.43. The company’s 50-day moving average is $166.73 and its 200 day moving average is $150.14.
ICU Medical (NASDAQ:ICUI – Get Free Report) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $0.46. ICU Medical had a net margin of 1.39% and a return on equity of 7.91%. The firm had revenue of $547.88 million for the quarter, compared to the consensus estimate of $533.44 million. During the same quarter in the prior year, the firm posted $2.10 earnings per share. The business’s revenue was up .5% on a year-over-year basis. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. As a group, analysts anticipate that ICU Medical, Inc. will post 7.22 EPS for the current year.
Insider Activity
In related news, VP Daniel Woolson sold 5,417 shares of the stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $181.33, for a total transaction of $982,264.61. Following the sale, the vice president directly owned 17,062 shares of the company’s stock, valued at $3,093,852.46. This trade represents a 24.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Elisha Finney sold 378 shares of ICU Medical stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $182.48, for a total value of $68,977.44. Following the completion of the sale, the director owned 4,871 shares of the company’s stock, valued at $888,860.08. The trade was a 7.20% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 21,830 shares of company stock valued at $3,905,003. Corporate insiders own 2.10% of the company’s stock.
Institutional Trading of ICU Medical
Several hedge funds have recently bought and sold shares of the stock. BlackRock Inc. bought a new stake in ICU Medical in the 2nd quarter valued at $550,250,000. Jupiter Topco LLC purchased a new stake in ICU Medical in the 2nd quarter worth $407,786,000. Janus Henderson Group PLC lifted its stake in ICU Medical by 3.9% in the 1st quarter. Janus Henderson Group PLC now owns 2,676,012 shares of the medical instruments supplier’s stock worth $345,607,000 after purchasing an additional 99,256 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in ICU Medical by 6.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 983,802 shares of the medical instruments supplier’s stock worth $127,053,000 after purchasing an additional 63,026 shares in the last quarter. Finally, Bank of America Corp DE bought a new position in shares of ICU Medical during the 2nd quarter valued at about $54,059,000. Institutional investors own 96.10% of the company’s stock.
ICU Medical Company Profile
ICU Medical, Inc develops, manufactures and sells medical devices and systems used in infusion therapy, critical care and oncology. Its products are designed to support the delivery of fluids, medications and nutrition while helping healthcare providers improve safety and efficiency in clinical settings.
The company’s portfolio includes infusion pumps, dedicated and non-dedicated administration sets, needle-free connectors, intravenous solutions and other infusion consumables. ICU Medical also offers products for critical care monitoring and vascular access, as well as closed-system transfer devices and related technologies used in the preparation and administration of hazardous drugs.
Founded in 1984, ICU Medical has expanded through internal development and acquisitions, including the acquisition of Hospira’s infusion systems business in 2017 and Smiths Medical in 2022.
Featured Stories
- Five stocks we like better than ICU Medical
- GM Beat and Added a $20 Billion Buyback—Why Did the Stock Fall?
- Intercepting Growth: Karman Secures $218M Lockheed Martin Deal
- Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs
- Chip Stocks Have Pulled Back—Here’s How 3 Semiconductor ETFs Stack Up for Investors
Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.
